| 10x Genomics–Merck (DE): CRISPR technology, 202006 collab launch integrated solution for CRISPR research |
2020-06-10 |
| 1BillionLives–Austria (govt): grant, 202307–202606 3y grant €2m from FFG for Flinn |
2023-07-01 |
| 1BillionLives–Cherry Ventures: investment, 202408 seed financing round totalling €6m incl lead investor Cherry Ventures |
2024-08-03 |
| 1BillionLives–OTHER: investment, 202408 seed financing round totalling €6m incl business angels incl M Weber + M Reitermann |
2024-08-03 |
| 1BillionLives–Paua Ventures: investment, 202212 pre-seed financing round of Flinn totalling €1.8m incl co-lead investor Paua Ventures |
2022-12-01 |
| 1BillionLives–SEVERAL: investment, 202212 pre-seed financing round €1.8m of Flinn led by Speedinvest + Paua Ventures |
2022-12-01 |
| 1BillionLives–SEVERAL: investment, 202408 seed financing round €6m of Flinn led by Cherry Ventures |
2024-08-03 |
| 1BillionLives–Speedinvest: investment, 202212 pre-seed financing round totalling €1.8m of Flinn incl co-lead investor Speedinvest |
2022-12-01 |
| 1BillionLives–Speedinvest: investment, 202408 seed financing round totalling €6m incl existing + co-investor Speedinvest |
2024-08-03 |
| 1BillionLives–SquareOne: investment, 202408 seed financing round totalling €6m incl existing + co-investor SquareOne VC |
2024-08-03 |
| 2bind–Dynamic Biosensors: switchSENSE technology, 202209– collab technology-service with 2bind using HeliX biosensor system as certified beta customer |
2022-09-01 |
| 3a-Diagnostics–XPhyto Therapeutics: investment, 202107– 202110 acqisition 100% €400k upfront + €3.5m at closing ANNOUNCED |
2021-07-20 |
| 3SBio–Numab: antibody cancer drug, 201912– collab developm + commercialisation with Sunshine Guojian for multi-specific Abs in Greater China |
2019-12-12 |
| 4basebio–Circio: synthetic DNA vectors, 202501– collab developm integration of circVEC system with Hermes platform + hpDNA + opDNA |
2025-01-21 |
| 4basebio–MC Services: public relations, 202007 service existent MC Services is IR + media contact for 4basebio (formerly Expedeon AG) |
2020-07-28 |
| 4D Lifetec–SEVERAL: investment, 202207 financing round Series B CHF1.9m first closing from existing + new investors + strategic partners |
2022-07-11 |
| 4Pharma–BC Platforms: investment, 202306 acquisition €na of 4Pharma by BC Platforms |
2023-06-01 |
| 4SC–Optimum Strategic Communications: public relations, 202309 service existent by Optimum |
2023-09-27 |
| 4SC–SEVERAL: investment, 201906 capital increase €11m with 4.677m new shares at €2.37/share |
2019-06-11 |
| 4SC–SEVERAL: investment, 201910–201911 capital increase €22.4m net €22m with 10.65m new shares at €2.1/share with subscription rights |
2019-10-07 |
| 4SC–Strüngmann Group: investment, 201910 capital increase totalling €22.4m net €22m incl subscription rights for Santo Holding + ATS |
2019-10-07 |
| 4Teen4 Pharmaceuticals–Brandenburg (govt): investment, 201912 financing round Series A totalling €6.9m incl lead investor Brandenkapital GmbH |
2019-12-05 |
| 4Teen4 Pharmaceuticals–SEVERAL: investment, 201912 financing round Series A €6.9m led by Brandenkapital GmbH with private investors + business angels |
2019-12-05 |
| 908 Devices–Manufacturing USA: grant, 201907– grant from NIIMBL for developm of at-line bioreactor process analytics tog w MilliporeSigma et al |
2019-07-25 |
| 908 Devices–Sartorius: bioprocess control technology, 202106 collab product integration Rebel media analyzer with SIMCA data exploratory tool |
2021-06-22 |
| 908 Devices–Securecell: bioprocess control technology, 202106 collab product integration Rebel media analyzer with Lucullus PIMS |
2021-06-22 |
| A2 Biotherapeutics–Nextech: investment, 201911 emerges from stealh with financing round Series A totalling $57m incl investor Nextech Invest |
2019-11-05 |
| A2 Biotherapeutics–Nextech: investment, 202010 financing round Series B totalling $71.5m incl existing investor Nextech Invest |
2020-10-06 |
| A2 Biotherapeutics–Sam Brown: public relations, 202403 service existent by Sam Brown Inc |
2024-03-25 |
| A2 Biotherapeutics–SEVERAL: investment, 201911 emerges from stealh with financing round Series A $57m |
2019-11-05 |
| A2 Biotherapeutics–SEVERAL: investment, 202010 financing round Series B $71.5m |
2020-10-06 |
| a:head bio–red-stars.com data: investment, 201908– milestone-dependent 7-digit EUR seed investment by red-stars.com data AG in a:head bio AG |
2019-08-07 |
| a:head bio–SEVERAL: investment, 202410 financing round pre-Series A 7-digit EUR from existing + new investors |
2024-10-09 |
| Aalto Bio Reagents–Biosynth Carbosynth: investment, 202205 acquisition of Aalto by Biosynth Carbosynth |
2022-05-25 |
| AATec Medical–MC Services: public relations, 202310 service existent MC Services is media contact |
2023-10-31 |
| AATec Medical–SEVERAL: investment, 202307 seed financing round €2.7m from private investors + industry experts + family offices |
2023-07-17 |
| AaviGen–Hopp Group: investment, 202307 financing round Series B €17m from existing investor DH-LT Investments GmbH |
2023-07-26 |
| Abalos Therapeutics–Boehringer: investment, 201910 financing round Series A totalling €12m invl co-lead investor BIVF |
2019-10-15 |
| Abalos Therapeutics–High-Tech Gründerfonds: investment, 201910 financing round Series A totalling €12m incl co-investor HTGF |
2019-10-15 |
| Abalos Therapeutics–North-Rhine Westphalia (govt): investment, 201910 financing round Series A totalling €12m incl co-investor NRW.BANK |
2019-10-15 |
| Abalos Therapeutics–North-Rhine Westphalia (govt): investment, 201910 financing round Series A totalling €12m incl co-lead investor Gründerfonds Ruhr |
2019-10-15 |
| Abalos Therapeutics–SEVERAL: investment, 201910 financing round Series A €12m co-led by BIVF + Gründerfonds Ruhr |
2019-10-15 |
| Abalos Therapeutics–SEVERAL: investment, 202110 financing round Series A extension €32.5m led by Seventure Partners |
2021-10-14 |
| Abalos Therapeutics–Trophic Communications: public relations, 201910 service existent by Trophic |
2019-10-15 |
| AbbVie–Mission Therapeutics: DUB inhibitors, 201811– collab RnD + license option €na for Alzheimer’s + Parkinson’s diseases |
2018-11-15 |
| AbbVie–Temedica: digital patient companion app, 202308 collab launch of companion app Tami for patients with chronic IBD in Germany |
2023-08-02 |
| Abcalis–Germany (govt): grant, 201912 EXIST research transfer grant for founding from BMWi (plus ESF grant) |
2019-12-10 |
| abcr GmbH–Enzymicals: enzymes, 201803– collab distribution expansion ww catalogue sale of selected enzymes + enzyme-produced chemicals |
2018-03-01 |
| abcr GmbH–Enzymicals: enzymes, 201903– collab distribution expansion ww sale of all catalogue products of Enzymcials by acbr |
2019-03-04 |
| Abingworth–SEVERAL: investment, 202102 final closing at $465m of Abingworth Bioventures 8 Fund |
2021-02-03 |
| Abingworth–SEVERAL: investment, 202105 final closing at $582m of Abingworth Clinical Co-Development Fund 2 |
2021-05-10 |
| Abionic–SEVERAL: investment, 201808 financing round Series C CHF20m led by P Bottinelli + incl Investiere AG + ZKB + high net worth individuals |
2018-03-28 |
| Abivax–MC Services: public relations, 202309 service existent MC Services is European investor relations contact |
2023-09-29 |
| AbnomX–BioLizard: bioinformatics, 202404– collab strategic partnership with regard to complementary offerings |
2024-04-02 |
| Abolis Biotechnologies–Evonik: investment, 202409 financing round totalling €35m incl investor Evonik Venture Capital |
2024-09-12 |
| Abolis Biotechnologies–Germany (govt): investment, 202409 financing round totalling €35m incl investor DeepTech & Climate Fonds |
2024-09-12 |
| Abolis Biotechnologies–SEVERAL: investment, 202409 financing round €35m with BOLD L’Oréal VC Fund + Evonik Venture Capital et al |
2024-09-12 |
| AC Immune–Avidity Partners: investment, 202312 underwritten offering totalling $50.05m incl co-investor Avidity Partners |
2023-12-15 |
| AC Immune–BVF Partners: investment, 202312 underwritten offering totalling $50.05m incl lead investor BVF Partners LP |
2023-12-15 |
| AC Immune–LaVoieHealthScience: public relations, 201909– supply service existent US media relations by LHS |
2019-09-20 |
| AC Immune–LifeSci: public relations, 201909 supply service existent European investor + media relations by LifeSci Advisors |
2019-09-20 |
| AC Immune–Lilly: credit, 201812 convertible note $50m in connection with license + collab agreement |
2018-12-12 |
| AC Immune–Redmile Group: investment, 202312 underwritten offering totalling $50.05m incl co-investor Redmile Group |
2023-12-15 |
| AC Immune–SEVERAL: investment, 202312 underwritten offering $50.05m led by BVF Partners with 14.3m common shares at $3.5/share |
2023-12-15 |
| AC Immune–StemPoint Capital: investment, 202312 underwritten offering totalling $50.05m incl co-investor StemPoint Capital LP |
2023-12-15 |
| AC Immune–WuXi Pharmatech: biologics contract manfucturing, 201812– collab strategic alliance biologics CDMO with WuXi Biologics |
2018-12-19 |
| Acousia Therapeutics–Golgi Neurosciences: investment, 202307 existent investment at time of spin-off of Golgi Neurosciences from Axxam |
2023-07-05 |
| Acquifer Imaging–Bruker: investment, 202301 acquisition $7.6m of Acquifer Imaging Gmbh + subsidiary Deltabyte GmbH by Bruker |
2023-01-05 |
| ActiTrexx–MC Services: public relations, 202103 service existent MC Services is media contact |
2021-03-02 |
| ActiTrexx–SEVERAL: investment, 202103 financing round Series A €3.5m led by LBBW Venture Capital GmbH |
2021-03-02 |
| Ada Health–Bayer: investment, 202105 financing round Series B totalling $90m incl lead investor Leaps by Bayer |
2021-05-27 |
| Ada Health–F4: investment, 202105 financing round Series B totalling $90m incl co-investor F4 |
2021-05-27 |
| Ada Health–Inteligo Bank: investment, 202105 financing round Series B totalling $90m incl co-investor Inteligo Bank |
2021-05-27 |
| Ada Health–Mutschler Ventures: investment, 202105 financing round Series B totalling $90m incl co-investor Mutschler Ventures |
2021-05-27 |
| Ada Health–Samsung: investment, 202105 financing round Series B totalling $90m incl co-investor Samsung Catalyst Fund |
2021-05-27 |
| Ada Health–SEVERAL: investment, 202105 financing round Series B $90m led by Leaps by Bayer |
2021-05-27 |
| Ada Health–Vitruvian Partners: investment, 202105 financing round Series B totalling $90m incl co-investor Vitruvian Partners |
2021-05-27 |
| ADC Therapeutics–Adagene: antibody technology, 201904– collab + license agreem €na using SAFEbody technology for ADC development |
2019-04-24 |
| ADC Therapeutics–Blue Owl Capital: credit, 202208–202908 senior secured term loan totalling up to $175m with $120m upfront from Owl Rock + Oaktree |
2022-08-15 |
| ADC Therapeutics–Blue Owl Capital: investment, 202208 equity investment $6.25m by certain funds of Owl Rock |
2022-08-15 |
| ADC Therapeutics–Deerfield: credit, 202005– convertible credit facility $115m in two conditionable disbursements of $65m + $50m |
2020-05-01 |
| ADC Therapeutics–Deerfield: investment, 202208– conversion of $115m convertible credit facility into equity |
2022-08-15 |
| ADC Therapeutics–Freenome: pharmacodiagnostics, 201908– collab developm multiomics biomarker for ADCT-402 treatment in DLBCL |
2019-08-26 |
| ADC Therapeutics–Oaktree: credit, 202208–202908 senior secured term loan totalling up to $175m with $120m upfront from Owl Rock + Oaktree |
2022-08-15 |
| ADC Therapeutics–SEVERAL: credit, 202208–202908 senior secured term loan up to $175m with $120m upfront tranche from Owl Rock + Oaktree |
2022-08-15 |
| ADC Therapeutics–SEVERAL: investment, 201906–201907 financing round Series E expansion $103m bringing total Series E to $303m |
2019-06-12 |
| ADC Therapeutics–SEVERAL: investment, 201909–201910 IPO up to approx $230m at NYSE WITHDRAWN 10/19 |
2019-09-06 |
| ADC Therapeutics–SEVERAL: investment, 202004–202005 IPO at NYSE $267.6m with 14.1m shares at $19/share |
2020-04-24 |
| Adcytherix–Bellevue: investment, 202406 seed financing round totalling €30m incl co-investor Pureos Bioventures |
2024-06-11 |
| Adcytherix–KKR: investment, 202406 seed financing round totalling €30m incl co-investor Dawn Biopharma |
2024-06-11 |
| Adcytherix–OTHER: investment, 202406 seed financing round totalling €30m incl participation from management |
2024-06-11 |
| Adcytherix–Pontifax: investment, 202406 seed financing round totalling €30m incl lead investor Pontifax Venture Capital |
2024-06-11 |
| Adcytherix–RA Capital: investment, 202406 seed financing round totalling €30m incl co-investor RA Capital Management |
2024-06-11 |
| Adcytherix–SEVERAL: investment, 202406 company launches with seed financing round €30m led by Pontifax Venture Capital |
2024-06-11 |
| Addex–SEVERAL: investment, 201909– filing of Nadaq lisiting of ADSs (without proposing to register any new issuance of secutiries) |
2019-09-24 |
| Addex–SEVERAL: investment, 202101 capital increase global offering $11.5m with 6.9m new shares (thereof 6.75m in form of ADSs |
2021-01-11 |
| Adeptrix–Bruker: investment, 202101 financing round Series A incl new + minority investor Bruker Corp |
2021-01-06 |
| Adeptrix–SEVERAL: investment, 202101 financing round Series A closed with new + minority investor Bruker Corp |
2021-01-06 |
| ADF/IDF–Symrise: investment, 201901– acquisition $900m by Symrise ANNOUNCED |
2019-01-31 |
| Adoram Therapeutics–Fongit: investment, 202502 pre-seed financing round incl co-lead investor Fongit – the Geneva incubator |
2025-02-25 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
